Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Maxcyte (MXCT) over the last 6 years, with Q3 2025 value amounting to $14000.0.

  • Maxcyte's Cash from Financing Activities fell 9385.96% to $14000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $963000.0, marking a year-over-year decrease of 5493.68%. This contributed to the annual value of $2.1 million for FY2024, which is 405.97% down from last year.
  • Per Maxcyte's latest filing, its Cash from Financing Activities stood at $14000.0 for Q3 2025, which was down 9385.96% from $154000.0 recorded in Q2 2025.
  • In the past 5 years, Maxcyte's Cash from Financing Activities ranged from a high of $184.6 million in Q3 2021 and a low of $14000.0 during Q3 2025
  • Its 5-year average for Cash from Financing Activities is $12.8 million, with a median of $444400.0 in 2022.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first skyrocketed by 7032590.61% in 2021, then crashed by 9975.92% in 2022.
  • Over the past 5 years, Maxcyte's Cash from Financing Activities (Quarter) stood at $1.2 million in 2021, then increased by 1.52% to $1.2 million in 2022, then tumbled by 59.77% to $493000.0 in 2023, then decreased by 16.43% to $412000.0 in 2024, then tumbled by 96.6% to $14000.0 in 2025.
  • Its Cash from Financing Activities was $14000.0 in Q3 2025, compared to $154000.0 in Q2 2025 and $383000.0 in Q1 2025.